Photo by bermixstudio from unsplash
In this issue of Blood, Kramer et al have provided a long-term update on the outcomes of patients enrolled in the German CLL Study Group CLL3X trial who underwent a… Click to show full abstract
In this issue of Blood, Kramer et al have provided a long-term update on the outcomes of patients enrolled in the German CLL Study Group CLL3X trial who underwent a matched related or unrelated allogeneic hematopoietic cell transplantation (allo-HCT) with a reduced-intensity fludarabine/alkylator-based approach for high-risk chronic lymphocytic leukemia (HR-CLL).1
Keywords:
cll;
cll still;
still relevant;
outcomes allografts;
allografts cll
Journal Title: Blood
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!